Table 3.

 Standardised incidence ratios (SIR) and 95% confidence intervals (CI) of oesophageal cancer and estimation of oesophageal adenocarcinoma in the study cohorts

	Oesophageal cancer				Estimation for oesophageal adenocarcinoma
	Obs OC	Exp OC	SIR (95% CI)	SIR ratio (95% CI)	Exp non-OAC	Exp* non-OAC	Est Obs OAC	Exp OAC	SIR (95% CI)	SIR ratio (95% CI)
All men and women (43 cancers)
Barrett’s	13	1.0	13 (7–22.2)	9.8 (4.3–21.6)	0.65	0.87	12.13	0.31	39.1 (20.2–68.3)	29.8 (9.6–106)
Oesophagitis	8	2.8	2.9 (1.2–5.6)	2.1 (0.8–5.3)	1.95	2.6	5.4	0.9	6.0 (1.9–14)	4.5 (1.0–19.6)
Reflux	6	2.7	2.2 (0.8–4.8)	1.7 (0.5–4.5)	1.87	2.49	3.51	0.86	4.1 (1.1–10.5)	3.1 (0.6–14.2)
Standard ref	16	12.0	1.3 (0.8–2.2)	1.00	8.16	10.88	5.12	3.84	1.3 (0.4–3.1)	1.00
Men (30 cancers)
Barrett’s	9	0.6	15 (6.9–28.5)	10.3 (3.8–26.5)	0.4	0.59	8.41	0.25	33.6 (14.5–66.3)	23.2 (6.6–89)
Oesophagitis	5	1.9	2.6 (0.9–6.1)	1.8 (0.5–5.5)	1.16	1.7	3.3	0.71	4.6 (1–13.6)	3.2 (0.5–16.3)
Reflux	4	1.8	2.2 (0.6–5.7)	1.5 (0.4–5)	1.12	1.64	2.36	0.68	3.5 (0.4–12.5)	2.4 (0.2–14.4)
Standard ref	12	8.2	1.5 (0.8–2.6)	1.00	5.07	7.45	4.55	3.1	1.5 (0.5–3.4)	1.00
Women (13 cancers)
Barrett’s	4	0.3	13.3 (3.6–34.1)	12.7 (2.4–68)	0.25	0.26	3.74	0.06	62.3 (22–130.6)	60.3 (5.9–2949)
Oesophagitis	3	1.0	3 (0.6–8.8)	2.9 (0.4–16.8)	0.79	0.83	2.17	0.19	11.4 (1.4–41.3)	10.9 (0.6–648)
Reflux	2	0.9	2.2 (0.3–8)	2.1 (0.2–14.7)	0.75	0.78	1.22	0.18	6.8 (0.2–37.8)	6.5 (0.08–511)
Standard ref	4	3.8	1.1 (0.3–2.7)	1.00	3.09	3.23	0.77	0.74	1.0 (0.03–5.8)	1.00

*Corrected.

Obs, observed; Exp, expected; OC, oesophageal cancer; OAC, adenocarcinoma.